This segment encompasses the core research and development activities focused on discovering and developing protein-based immunotherapies. Alpine Immune Sciences utilizes its expertise in protein engineering and directed evolution to create novel therapeutic candidates. Key technologies include the development of fusion proteins and engineered antibodies targeting key immune checkpoints and costimulatory molecules. Research efforts are concentrated on programs like ALPN-101, ALPN-202, and ALPN-303, which are designed to treat autoimmune diseases, cancer, and B cell-mediated inflammatory diseases, respectively. Clinical trials are a critical component of this segment, with ongoing studies evaluating the safety and efficacy of these therapies in various patient populations. The company's market positioning is strengthened by its strategic collaborations with companies like AbbVie and Adaptimmune. Future opportunities include expanding the pipeline with new therapeutic targets and advancing clinical programs through regulatory approvals. This segment addresses significant unmet medical needs in oncology and immunology, aiming to improve patient outcomes through innovative treatment approaches.

This segment focuses on the execution of clinical trials and the regulatory processes required to bring new immunotherapies to market. Alpine Immune Sciences conducts clinical trials across various phases to evaluate the safety, efficacy, and optimal dosing of its drug candidates. The company employs rigorous methodologies to ensure data integrity and patient safety throughout the trial process. This segment involves close collaboration with regulatory agencies, such as the FDA, to obtain necessary approvals for clinical trials and eventual product commercialization. The therapeutic areas covered include oncology, autoimmune diseases, and inflammatory disorders. The patient impact is significant, as successful clinical trials can lead to the availability of new and effective treatments for patients with these conditions. Market positioning is enhanced by the company's ability to navigate the complex regulatory landscape and demonstrate the clinical value of its therapies. Future opportunities include expanding the clinical trial portfolio and accelerating the path to market for promising drug candidates. This segment is crucial for translating scientific discoveries into real-world patient benefits.